The CpG Island Methylator Phenotype May Confer a Survival Benefit in Patients With Stage II or III Colorectal Carcinomas Receiving Fluoropyrimidine-Based Adjuvant Chemotherapy
BMC Cancer - United Kingdom
doi 10.1186/1471-2407-11-344
Full Text
Open PDFAbstract
Available in full text
Date
August 10, 2011
Authors
Publisher
Springer Science and Business Media LLC